Member Info for notaflipper

Yes it does make for interesting reading when aliases argue and like their alternate personas and hard to keep track.

Scale of the disappointment over here seems overdone when one considers that these figures have been known since October and have not changed. So the drop seems more related to what was not supplied e.g. break-even, contract awards, regulatory roll-out and capacity expansion than what was. With FY targets in line to be met, if one can await to sell their shares in April '21 that would be better. I would believe sp predictions of 20p+ by then would me more realistic than some of the posts we've seen here of late. Interestingly the 21% increase in general administrative expenses to £5.2m has been driven by the the transition costs associated with the switchover of European customers to the newly launched IONA Nx NIPT. One has to imagine this will continue into H2 however will be balanced out with IONA Nx which will help to spur on NIPT sales in the Patent Pool areas. I would have hoped for more on US roll-out of IONA Nx, DPYD and Clarigene. As mentioned before I don't think regulatory approval for Clarigene is being sought but I believe IONA Nx and DPYD are are available via IBL under RUO. It was encouraging to hear that they have two active US partners for our next-generation sequencing based Flex software and anticipate that reproductive health-based clinical services will launch in the first half of calendar 2021.

It does seem strange why they tried to get the Half Year results out this week as looking at the sp reaction you would have thought they would have awaited the Xmas quiet period next week. Hopefully now that the results are out of the way we should potentially get news soon to move on.
GLA to all LTHs

You guys need to chill and stop getting so worked up. Still adding everyday and still expecting 50p by Y/E.
GLA

I agree it is not relative. Sadly I don't think we will be getting a standalone Covid diagnostic update so assume this will be rolled into Half Year results. What would help is to have a breakdown by tests sold and then laboratory tests processed internally and externally. There has been some suggestions that YGEN is involved in more than the formal RNS states as per the webinar where it was suggested they were (potentially)making a contribution to moon-shot. So let's hope for the best on Thursday for all LTHs.

Agreed we would not be in a Closed period if yesterday's RNS was it and there was no further material news expected before Y/E.

They cannot if we are still in a Closed Period and they know of more expectant news.
You guys need to take a chill pill. Still expecting 50p+ by Xmas

Sold too quick.
Enjoy the ride chaps.

With a 10-person BoD and 12-person Senior Management Team, LR's Non-Exec commitments cannot be an excuse for a lack of senior capacity. It has been a given for many years with any AR company that those involved are completely incestuous and are Directors, Shareholders or Non-Exec each other companies like My Health Checked. Incidentally their website is showing more Covid tests in stock and these seem to be shifting if you look every other day.

Shareholders would be better to focus on why some opportunities to leverage the opportunities these Non-Exec positions give. For example via Abingdon there is a relationship with senior management at GDR where Genedrive's SARS-CoV-2 POC Kit is being designed to detect SARS-CoV-2 amplified directly from a saliva sample without the need to extract viral RNA. Similarly how Clarigene, Iona Nx and DPYD cannot have FDA approval sought at this stage whereas Abingdon Health has done so is beyond me.

With the Half Year results coming just before the Christmas quiet period it really is a crack-shoot whether the hoped for contract news, break-even expectations and so on does come. The numbers will not change just the Post Period Update and Forward Looking Statements. Good news is that there's a presentation which shows some positivity. The two-days notice is just a bit redundant with the best will but perhaps not as redundant as negative posts which still anticipate a 25% rise in less 4 days of trading. Quite a shame to see this BB reduced to aliases arguing between their alternate personas and liking each other's posts but it will make for interesting reading on Thursday.

Some highlights:
· Cash at Period End increased from £41.6m to £75.8m following disposal of Canadian business
· Number of instructions increased to 35,387 from 32,850
· Gross Profit margin increased to 67.0% from 63.7%
· 4.8%5 share of properties sold by volume
· Total instructions increased by 8% to 35,387 (H1 20: 32,850)
· Instructions increased by 20% in the five months since May, post the market reopening

Bought back in.
Have to say even for a trader's stock some of these posts are getting a bit obvious with posters who had orders planned for a retrace still looking to get those orders filled. Long story short none of these posters were expecting news to come before Xmas and were hoping for a retrace to make an easy profit. Most people staying on side due to macro concerns. With the savage media coverage saying the sale was looking unlikely or at sub-£350m it is laughable that the sale was priced. Key drivers in the short term will be the macro news this week on Brexit where I am expecting a deal but not before Xmas so 1 more week. Take this and any small retrace as a gift to buy in at a reasonable price as Company does have a sense of determination around it and expecting further news before Year End.
Key thing will be what happens now with Sandbar's and Citadel's reducing short.

Glad that the prediction that the sale would happen before Xmas came through and at a decent price to make a significant contribution to save a rights issue. Bit amazed by the weak, and declining, market reaction though. Any thoughts?

Still adding here. Good luck for Tuesday all.

Cheers for your thoughts and clarification pacman & Ella

I read the Government Website note differently as the revised UKAS accreditation is to cover "new" test providers (e.g. care homes with nursing staff, private healthcare facilities) so that they can get accredited quickly to carry out tests.

YGEN has 2 CQC accredited labs. The 2nd only opening in Oct 2020. The CQC is a more onerous and demanding accreditation than UKAS which is also more a national, than international, standard. Citilabs being CQC accredited allowed them to perform diagnostics and screening procedures of their Yourgene Genomic Services and COVID-19 testing services. As shareholders here had 2 RNS in Sep and Oct about the points I mention above you should be able to refer to these in querying IR on the implication of the UKAS standard.

Yourgene Health is already registered with the Care Quality Commission (CQC)

As I tried to explain the other day the broker let it slip that he could only take a long position as shorts were no longer available as there were no shares for them to borrow on this market.

Trading range consolidation during last 3 weeks in advance of Interim results. Some noise from Brexit trepidation inevitably thrown in across the market. Not much fun but suggests accumulation of shares. Not long to go till Tuesday. Will be soon time to place your bets either way.

Spoke to the broker as was looking to put a Spread Bet on this earlier today. It was locked out for most of the day and when we finally chatted he let it slip that he could only take a long position as shorts were no longer available as there were no shares for them to borrow on this market. Surprising as this usually happens when a correction is coming but there's no shorts or short tracker so couldn't understand why there was no shares for them to borrow. Not in for now and standing on the side lines to see if it retraces back to the trading pattern beginning. Seems like a lot of automatic trades are running the show here but perhaps this may change if material news is released.

As suspected it does look like there's a background buyer who is buying at mid-price the shares being off-loaded by PIs to maintain the 16p trading floor and to not affect the sp.
GLA to all LTHs

Financial Calendar on YourGene's website still says December. As others have suggested it is expected later in the month with no notice for potential material news. I find the lack of visibility on reporting timescales more damaging to Investor Confidence than just providing a circumscribed trading outlook statement and post accounting period update. The numbers have not changed so far better to just recycle the October Half Year trading update so they could just provide another Trading Update in January as they hope for material news. Many companies have been providing monthly trading updates during the pandemic so it is not strange.

I expect HY results in quiet period, with perhaps a further Covid trading update early next year. Some could argue that if HY results does not include new material news this could not matter as long as this came soon thereafter. I say this last point as companies that pursue an acquisitive growth strategy 'usually' try to inflate their sp with investor communications as then you create a positive feedback loop where each acquisition creates sp growth, which means that future placings for acquisition result in less dilution.

I had thought that the changes due to Covid covered under the Temporary Modifications Regulations Act 2020 were related to extension being given to the filing of accounts with Companies House but perhaps wrong.
https://www.gov.uk/government/publications/the-companies-etc-filing-requirements-temporary-modifications-regulations-2020/temporary-changes-to-companies-house-filing-requirements

Stamp duty holiday is driving sales in order to beat deadline in March 2021. From Q3 update in October we know instructions are already up and "a pleasing profit" performance is to be expected to be announced in unaudited half year results next week on Tuesday 15 December 2020.